Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

JPM 2021: Medtronic, Biogen, Edwards LifeSciences, Guardant Health, Illumina

Executive Summary

The annual J.P. Morgan Healthcare Conference includes presentations from many major medtech companies outlining their growth strategies and expectations for 2021. Here are some of the highlights from the first day of the meeting.

You may also be interested in...



J.P. Morgan 2021: The Show Must Go On

The J.P. Morgan Healthcare Conference will be a virtual event but the industry's biggest business meeting will still lay the groundwork for the year ahead.

Edwards Returns To Growth In The Third Quarter

The company’s third-quarter sales were up 4% year-over-year as transcatheter aortic valve replacement procedure volumes returned to pre-pandemic levels.

Medtronic Lays Out Plans To Achieve 5%+ Annual Growth

The medtech giant offered additional details on its ongoing restructuring plan intended to make the company more competitive.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS150923

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel